Jeon Sang Hoon, Kim Hyung Woo, Kim Bit Na, Kang Nahyeon, Yeo Chang Dong, Park Chan Kwon, Kim Young Kyoon, Lee Yoon Ho, Kim Tae-Jung, Lee Kyo Young, Lee Sug Hyung, Park Jong Y, Park Mi Sun, Yim Hyeon Woo, Kim Seung Joon
Division of Pulmonology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
The Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
In Vivo. 2019 Mar-Apr;33(2):595-603. doi: 10.21873/invivo.11516.
BACKGROUND/AIM: This study compared the efficacy of PANAMutyper™, a novel technology that integrates PNAClamp™ and PANA S-Melting™, and PNAClamp™ alone for the detection of EGFR mutations in lung cancer patients.
PANAMutyper™ and PNAClamp™ were used to assess the EGFR mutation status in tissue, cell block, pleural effusion, and blood samples of 90 lung cancer patients with malignant pleural effusion.
PANAMutyper™ detected more EGFR mutations than PNAClamp™, especially in body fluids (pleural effusion and serum). Patients with additional EGFR mutations detected using PANAMutyper™ had a favorable response to EGFR-tyrosine kinase inhibitor (TKI) treatment.
The diagnostic performance of PANAMutyper™ was superior to that of PNAClamp™ for the detection of EGFR mutations. It was also better at identifying lung cancer patients with malignant pleural effusion who were likely to benefit from EGFR-TKI treatment.
背景/目的:本研究比较了整合了PNAClamp™和PANA S-Melting™的新技术PANAMutyper™与单独使用PNAClamp™检测肺癌患者表皮生长因子受体(EGFR)突变的效果。
使用PANAMutyper™和PNAClamp™评估90例伴有恶性胸腔积液的肺癌患者的组织、细胞块、胸腔积液及血液样本中的EGFR突变状态。
PANAMutyper™检测到的EGFR突变比PNAClamp™更多,尤其是在体液(胸腔积液和血清)中。使用PANAMutyper™检测到额外EGFR突变的患者对EGFR酪氨酸激酶抑制剂(TKI)治疗有良好反应。
在检测EGFR突变方面,PANAMutyper™的诊断性能优于PNAClamp™。在识别可能从EGFR-TKI治疗中获益的伴有恶性胸腔积液的肺癌患者方面,它也表现更佳。